

**THE PRODUCTION AND PURIFICATION OF D6  
AND DARC CHEMOKINE DECOY RECEPTOR  
RECOMBINANT PROTEINS AND THEIR EFFECTS  
ON MIGRATION AND INVASION IN MDA-MB-231  
AND MCF-7 CELLS**

**TAN WEE YEE**

**UNIVERSITI SAINS MALAYSIA**

**2018**

**THE PRODUCTION AND PURIFICATION OF D6  
AND DARC CHEMOKINE DECOY RECEPTOR  
RECOMBINANT PROTEINS AND THEIR EFFECTS  
ON MIGRATION AND INVASION IN MDA-MB-231  
AND MCF-7 CELLS**

by

**TAN WEE YEE**

**Thesis submitted in fulfillment of the requirements  
for the degree of  
Doctor of Philosophy**

**July 2018**

## **ACKNOWLEDGEMENT**

First of all, I would like to express my sincere thanks and deepest gratitude to my main supervisor, Dr. Chew Ai Lan, for spending her times and efforts on supervising me throughout the research. Without her dedicated guidance and constructive advice, this project will not be completed smoothly. Again, hearty thanks to Dr Chew for being a great supervisor.

Not forgetting my co-supervisors, Dr Khoo Boon Yin for her valuable advice on cell culture studies and also Professor Darah Ibrahim from School of Biological Sciences. The helps provided by scientific, academic and administrative staff of INFORMM throughout the study are highly appreciated.

Special gratitude goes to National Science Fellowship awarded by Ministry of Science, Technology and Innovation (MOSTI) which covered my tuition fees and living expenses in USM. Besides, the Exploratory Research Grant Scheme (ERGS) from the Ministry of Higher Education Malaysia (grant no: 203/CIPPM/6730059) is acknowledged for funding this work.

Furthermore, I would like to convey my sincere thanks to all of my best fellow colleagues and friends in the lab and institute who never fail in lending me a hand when I was in the dark. The support, help and more importantly, the valuable friendship and also the great time we spent together, will not be forgotten.

Last but not least, I dedicate this milestone to my family, husband and daughter. Million of thanks to my family for helping me to look after my daughter while I was working in the lab. This journey will not be possible without the unfailing love, care and encouragement from my beloved husband. To my lovely daughter who has taught me to become a better parent and person, you are forever my source of motivation. Thank you!

## TABLE OF CONTENTS

<b>ACKNOWLEDGEMENT</b>	<b>ii</b>
<b>TABLE OF CONTENTS</b>	<b>iv</b>
<b>LIST OF TABLES</b>	<b>xii</b>
<b>LIST OF FIGURES</b>	<b>xiii</b>
<b>LIST OF SYMBOLS, ABBREVIATIONS AND ACRONYMNS</b>	<b>xx</b>
<b>ABSTRAK</b>	<b>xxii</b>
<b>ABSTRACT</b>	<b>xxv</b>
<b>CHAPTER ONE: INTRODUCTION</b>	<b>1</b>
1.1 Breast cancer	1
1.1.1 Breast cancer in Malaysia	2
1.1.2 Breast cancer studies in Malaysia	4
1.2 Chemokines and chemokine receptors in cancer	5
1.2.1 CCL2 and breast cancer	12
1.3 Roles of chemokines and chemokine receptors in cancer cell migration and invasion	15
1.4 Decoy chemokine receptor proteins	17
1.4.1 D6	19
1.4.2 DARC	24
1.5 Current studies on D6 and DARC	28
1.6 Introduction to expression system	31
1.6.1 Prokaryotic expression system	32

1.6.2	Eukaryotic expression system	33
	1.6.2(a) Mammalian expression system	33
	1.6.2(b) Yeast expression system	33
1.7	<i>Pichia pastoris</i> and the expression of heterologous proteins	34
1.8	Statement of problems and rationale of the study	37
1.9	Objectives of the study	40
<b>CHAPTER TWO: MATERIALS AND METHODS</b>		<b>41</b>
2.1	Design of study	41
2.2	Materials	46
	2.2.1 Microorganisms	46
	2.2.2 Cell line	46
	2.2.3 Plasmids	46
	2.2.4 Oligonucleotides	46
2.3	Common methods	50
	2.3.1 Material weighing	50
	2.3.2 pH determination	50
	2.3.3 Optical density determination	50
	2.3.4 Sterilization	50
2.4	Basic microbiology methods	51
	2.4.1 Maintenance of <i>E.coli</i> strain	51
	2.4.2 Maintenance of <i>P. pastoris</i> strain	51
	2.4.3 Preparation of glycerol stocks	51

2.4.4	Preparation of <i>E. coli</i> electrocompetent cells	52
2.4.5	Preparation of <i>E. coli</i> chemical competent cells	53
2.4.6	Preparation of <i>P. pastoris</i> electrocompetent cells	53
2.5	Basic cell culture based methods	54
2.5.1	Cell counting	54
2.5.2	Seeding of cells	54
2.5.3	Splitting of cells	55
2.5.4	Cell freezing	55
2.6	Basic molecular biology based methods	56
2.6.1	Propagation of plasmids	56
2.6.2	Purification of plasmids	57
2.6.3	Polymerase Chain Reaction (PCR) amplification of DNA	58
2.6.3(a)	Colony PCR	59
2.6.3(b)	Gradient PCR	59
2.6.4	Separation of DNA by agarose gel electrophoresis	60
2.6.5	Purification of DNA from agarose gel	61
2.6.6	Purification of PCR products	61
2.6.7	Concentration of DNA by ethanol precipitation	62
2.6.8	Restriction enzyme digestion	63
2.6.9	Ligation of DNA fragments	63
2.7	Basic <i>In Silico</i> based methods	64
2.7.1	Mapping of restriction enzyme recognition sites	64
2.7.2	Multiple sequence alignment	64

2.8	Basic protein based methods	65
2.8.1	Preparation of protein samples	65
2.8.1(a)	Extracellular proteins	65
2.8.1(b)	Intracellular proteins	65
2.8.2	Analysis	66
2.8.2(a)	SDS-PAGE	66
2.8.2(b)	Western Blot	68
2.8.2(c)	Indirect ELISA	69
2.9	Analytical methods	70
2.9.1	Quantification of RNA concentration	70
2.9.2	Quantification of DNA concentration	70
2.9.3	Measurement of cell dry weight	71
2.9.4	Determination of total protein concentration	71
2.10	Molecular cloning of recombinant D6 and DARC	71
2.10.1	Maintenance of cell lines	71
2.10.2	Purification of RNA from cell line	72
2.10.3	Synthesis of cDNA	73
2.10.4	PCR screening for D6 and DARC	73
2.10.5	Generation of full length cDNA	76
2.10.5(a)	Primer design	76
2.10.5(b)	One-step reverse transcription PCR with Pfu DNA polymerase	77
2.10.5(c)	PCR with Phusion DNA polymerase	78

2.10.6	TA cloning	79
2.10.6(a)	DNA sequencing	80
2.10.6(b)	Site-directed mutagenesis	81
2.10.7	Generation of recombinant yeast expression vector and DNA sequencing	82
2.10.7(a)	Selecting expression vector	82
2.10.7(b)	Preparation of transforming DNA	82
2.10.7(c)	Transformation by electroporation	83
2.10.7(d)	DNA sequencing	84
2.10.8	Analysis of <i>P. pastoris</i> integrants	84
2.10.8(a)	Antibiotic screening	84
2.10.8(b)	PCR analysis	85
2.10.9	Selection of clones with high Zeocin <sup>TM</sup> resistance	86
2.11	Expression and purification of recombinant D6 and DARC	86
2.11.1	Initial expression profile of recombinant D6 and DARC	87
2.11.2	Detection of recombinant proteins	88
2.11.3	Improvement of physical parameters for the production of recombinant D6 and DARC in shake flask system	88
2.11.3(a)	Incubation temperature	89
2.11.3(b)	pH of medium	89
2.11.3(c)	Size of inoculum	89
2.11.3(d)	Incubation time	90
2.11.4	Improvement of chemical parameters for the production of	90

recombinant D6 and DARC in shake flask system	
2.11.4(a) Feeding frequency of inducer	91
2.11.4(b) Concentration of inducer	91
2.11.4(c) Addition of casamino acids	92
2.11.4(d) Growth profile under improved physical and chemical conditions	92
2.11.5 Purification of recombinant D6 and DARC	92
2.11.5(a) Concentration of crude protein sample	92
2.11.5(b) His-tag purification using Cobalt resin	93
2.11.5(c) Detection and identification of recombinant proteins	95
2.12 Applications of recombinant D6 and DARC in cell culture studies	95
2.12.1 MTT Assay	95
2.12.2 Wound healing assay	96
2.12.3 Determination of CCL2 expression level via ELISA	96
2.12.4 Migration assay	98
2.12.5 Invasion assay	101
2.13 Biostatistical analysis	102
<b>CHAPTER THREE: RESULTS</b>	<b>104</b>
3.1 Molecular cloning of recombinant D6 and DARC	104
3.1.1 Purification of RNA from cell line	104
3.1.2 PCR screening for D6 and DARC	105
3.1.3 Generation of full length cDNA	107

3.1.3(a) Primer design	110
3.1.3(b) Mapping of restriction enzyme recognition sites	114
3.1.3(c) One-step reverse transcription PCR with Pfu DNA polymerase	117
3.1.3(d) PCR with Phusion DNA polymerase	121
3.1.4 TA cloning	123
3.1.4(a) DNA sequencing and site-directed mutagenesis	126
3.1.5 Generation of recombinant yeast expression vector	127
3.1.5(a) DNA sequencing	134
3.1.6 Analysis of <i>P. pastoris</i> integrants	135
3.1.7 Selection of clones with high Zeocin <sup>TM</sup> resistance	140
3.2 Expression and purification of recombinant D6 and DARC	144
3.2.1 Initial expression profile of recombinant D6 and DARC	144
3.2.2 Improvement of physical parameters for the production of recombinant proteins in shake flask system	148
3.2.2(a) Incubation temperature	148
3.2.2(b) pH of medium	155
3.2.2(c) Size of inoculum	158
3.2.2(d) Incubation time	162
3.2.3 Improvement of chemical parameters for the production of recombinant proteins in shake flask system	165
3.2.3(a) Feeding frequency of inducer	165
3.2.3(b) Concentration of inducer	170

3.2.3(c) Addition of casamino acids	173
3.2.3(d) Growth profile under improved physical and chemical conditions	176
3.2.4 Purification of recombinant D6 and DARC	180
3.2.4(a) His-tag purification using Cobalt resin	180
3.2.4(b) Detection of recombinant proteins	185
3.3 Applications of recombinant D6 and DARC in cell culture studies	189
3.3.1 MTT Assays	189
3.3.2 Wound healing assays	193
3.3.3 Determination of CCL2 expression level via ELISA	205
3.3.4 Migration assays	211
3.3.5 Invasion assays	219
<b>CHAPTER FOUR: DISCUSSION</b>	<b>224</b>
4.1 Molecular cloning of recombinant D6 and DARC	224
4.2 Expression and purification of recombinant D6 and DARC	233
4.3 Applications of recombinant D6 and DARC in cell culture studies	246
<b>CHAPTER FIVE: CONCLUSION AND SUGGESTIONS FOR FUTURE STUDIES</b>	<b>259</b>
<b>REFERENCES</b>	<b>265</b>
<b>APPENDICES</b>	

## LIST OF TABLES

		<b>Page</b>
Table 2.1	Oligonucleotides used in the study	49
Table 2.2	Forward and reverse primers of D6 and DARC	74
Table 2.3	PCR thermo profiles for amplification of D6 and DARC	75
Table 2.4	Fixed parameters of initial expression profile of recombinant D6 and DARC	88
Table 2.5	Improved physical parameters incorporated in shake flask system	91
Table 3.1	Primer sequences	110
Table 3.2	Noncutters for D6 and DARC	115
Table 3.3	Primer pairs incorporated with appropriate restriction sites	116
Table 3.4	Initial expression profile of the different recombinant GS115 clones	147
Table 3.5	The summary of optimized conditions for Western blot using Anti-His-Antibody on recombinant D6, DARC and mutated DARC	187
Table 3.6	The summary of optimized conditions for Western blot using specific primary antibody on recombinant D6, DARC and mutated DARC	187
Table 3.7	Wound gap observed at indicated time points after treatment with recombinant protein	194

## LIST OF FIGURES

	<b>Page</b>
Figure 1.1 The age-standardization rate (ASR) by state in Malaysia, 2007-2011	3
Figure 1.2 Chemokines are classified into four major groups, namely CXC, CC, CX3C and XC (where X is any amino acid)	6
Figure 1.3 The interaction of chemokine receptors with endothelial cells	8
Figure 1.4 The binding of chemokine receptor to respective ligand elicits a cascade of signaling pathway	10
Figure 1.5 Roles of CCL2 on the malignancy of breast cancer	14
Figure 1.6 A global illustration of the routes taken by chemokines with different types of receptors	18
Figure 1.7 The coordinated actions of DARC and D6 in peripheral tissue	21
Figure 1.8 D6, the decoy chemokine receptor proteins compete with signaling chemokine receptor for ligands	23
Figure 1.9 DARC, the decoy chemokine receptor protein competes with signaling chemokine receptor for ligands	26
Figure 2.1 Flowchart of the study design	45
Figure 2.2 The vector map of pTZ57R/T	47
Figure 2.3 The vector maps of pPICZ A, pPICZ $\alpha$ A and pPICZ $\alpha$ B	48
Figure 2.4 The illustration of a Boyden chamber system	99
Figure 3.1 Total RNA of MDA-MB-231	104
Figure 3.2 Initial PCR screening of D6 and DARC	106

Figure 3.3	Nucleotide sequence view for CCBP2 and DARC	108
Figure 3.4	The location of designed primers	112
Figure 3.5	Amplification of D6 and DARC using designed primers incorporated with restriction sites	118
Figure 3.6	Gel image of gradient PCR products of (a) D6 and (b) D6 $\alpha$	119
Figure 3.7	Gel image of gradient PCR products of (a) DARC and (b) DARC $\alpha$	120
Figure 3.8	Amplification of DARC and DARC $\alpha$ with Phusion DNA polymerase	122
Figure 3.9	Gel image of agarose gel purification results for amplicons of DARC and DARC $\alpha$	122
Figure 3.10	Gel image of double digest results for (a) TA-D6 and (b) TA-D6 $\alpha$ clones	124
Figure 3.11	Gel image of double digest results for (a) DARC and (b) DARC $\alpha$ clones, amplified under One-step RT PCR with Pfu DNA polymerase	125
Figure 3.12	Gel image of double digest results for (a) pPICZ-D6 and (b) pPICZ-D6 $\alpha$ clones	130
Figure 3.13	Gel image of double digest result for (a) pPICZ-DARC and (b) pPICZ-DARC $\alpha$ clones	131
Figure 3.14	Gel image of double digest results for site-directed mutated clones of (a) DARC and (b) DARC $\alpha$	132
Figure 3.15	Gel image of double digest results on (a) pPICZ-DARC-Phusion	133

	and (b) pPICZ-DARC $\alpha$ -Phusion	
Figure 3.16	Gel image of PCR analysis for (a) D6 and (b) D6 $\alpha$ clones	137
Figure 3.17	Gel image of PCR analysis for (a) DARC and (b) DARC $\alpha$ clones	138
Figure 3.18	Gel image of PCR analysis for site-directed mutant (a) DARC and (b) DARC $\alpha$ clones	139
Figure 3.19	GS115-D6 and D6 $\alpha$ clones	141
Figure 3.20	GS115-DARC and DARC $\alpha$ clone	142
Figure 3.21	GS115-mutated DARC and DARC $\alpha$ clones	143
Figure 3.22	The effect of incubation temperature on the yield of recombinant D6	150
Figure 3.23	The effect of incubation temperature on the yield of recombinant DARC	152
Figure 3.24	The effect of incubation temperature on the yield of recombinant mutated DARC	154
Figure 3.25	The effect of pH of medium on the yield of recombinant D6	156
Figure 3.26	The effect of pH of medium on the yield of recombinant DARC	156
Figure 3.27	The effect of pH of medium on the yield of recombinant mutated DARC	157
Figure 3.28	The effect of inoculum size on the yield of recombinant D6	159
Figure 3.29	The effect of inoculum size on the yield of recombinant DARC	159
Figure 3.30	The effect of inoculum size on the yield of recombinant mutated DARC	161
Figure 3.31	The time course study on the yield of recombinant D6 after	163

	improvement of physical parameters	
Figure 3.32	The time course study on the yield of recombinant DARC after improvement of physical parameters	164
Figure 3.33	The time course study on the yield of recombinant mutated DARC after improvement of physical parameters	164
Figure 3.34	Effect of methanol feeding frequency on the yield of recombinant D6	167
Figure 3.35	Effect of methanol feeding frequency on the yield of recombinant DARC	168
Figure 3.36	Effect of methanol feeding frequency on the yield of recombinant mutated DARC	169
Figure 3.37	Effect of methanol concentration on the yield of recombinant D6	171
Figure 3.38	Effect of methanol concentration on the yield of recombinant DARC	172
Figure 3.39	Effect of methanol concentration on the yield of recombinant mutated DARC	172
Figure 3.40	Effect of casamino acids on the yield of recombinant D6	173
Figure 3.41	Effect of casamino acids on the yield of recombinant DARC	175
Figure 3.42	Effect of casamino acids on the yield of recombinant mutated DARC	175
Figure 3.43	Growth profile of recombinant D6 under optimized physical and chemical conditions	177
Figure 3.44	Growth profile of recombinant DARC under optimized physical	177

	and chemical conditions	
Figure 3.45	Growth profile of recombinant mutated DARC under physical and chemical conditions	178
Figure 3.46	Purification of recombinant D6 protein	182
Figure 3.47	Purification of recombinant DARC protein	183
Figure 3.48	Purification of recombinant mutated DARC protein	184
Figure 3.49	Western Blot results on different recombinant proteins expressed by recombinant GS115	188
Figure 3.50	Effect of purified recombinant D6 on the viability of selected breast cancer cell lines	190
Figure 3.51	Effect of purified recombinant DARC on the viability of selected breast cancer cell lines	192
Figure 3.52	Effect of purified recombinant mutated DARC on the viability of selected breast cancer cell lines	192
Figure 3.53	Effect of recombinant D6 on the migration of MCF-7 cells in wound healing assay	195
Figure 3.54	Effect of recombinant DARC on the migration of MCF-7 cells in wound healing assay	196
Figure 3.55	Effect of recombinant mutated DARC on the migration of MCF-7 cells in wound healing assay	196
Figure 3.56	Effect of recombinant D6 on the migration of MDA-MB-231 cells in wound healing assay	199
Figure 3.57	Effect of recombinant DARC on the migration of MDA-MB-231	199

	cells in wound healing assay	
Figure 3.58	Effect of recombinant mutated DARC on the migration of MDA-MB-231 cells in wound healing assay	200
Figure 3.59	Effect of combination of recombinant D6 and DARC on the migration of MDA-MB-231 and MCF-7 cells in wound healing assay	202
Figure 3.60	Effect of combination of recombinant D6 and mutated DARC in the migration of MDA-MB-231 and MCF-7 cells in wound healing assay	202
Figure 3.61	Effect of various recombinant proteins on the migration of MDA-MB-231 and MCF-7 cells in wound healing assay	204
Figure 3.62	Effect of recombinant D6 on CCL2 expression level in MDA-MB-231 and MCF-7 cells	206
Figure 3.63	Effect of recombinant DARC on CCL2 expression level in MDA-MB-231 and MCF-7 cells	206
Figure 3.64	Effect of recombinant mutated DARC on CCL2 expression level in MDA-MB-231 and MCF-7 cells	208
Figure 3.65	Effect of combinations of recombinant D6 and DARC on CCL2 expression level in MDA-MB-231 and MCF-7 cells	209
Figure 3.66	Effect of combinations of recombinant D6 and mutated DARC on CCL2 expression level in MDA-MB-231 and MCF-7 cells	209
Figure 3.67	Effects of recombinant proteins on CCL2 expression level in MDA-MB-231 and MCF-7 cells	210

Figure 3.68	Cell migration images under phase contrast microscope (400 × magnification)	212
Figure 3.69	Effect of recombinant D6 on the migration of MDA-MB-231 and MCF-7 cells via Boyden chamber assay	214
Figure 3.70	Effect of recombinant DARC on the migration of MDA-MB-231 and MCF-7 cells via Boyden chamber assay	215
Figure 3.71	Effect of recombinant mutated DARC on the migration of MDA-MB-231 and MCF-7 cells via Boyden chamber assay	215
Figure 3.72	Effect of combination of recombinant D6 and DARC on the migration of MDA-MB-231 and MCF-7 cells via Boyden chamber assay	217
Figure 3.73	Effect of combination of recombinant D6 and mutated DARC on the migration of MDA-MB-231 and MCF-7 cells via Boyden chamber assay	217
Figure 3.74	Effect of recombinant proteins on the migration of MDA-MB-231 and MCF-7 cells via Boyden chamber assay	218
Figure 3.75	Cell invasion images under phase contrast microscope (400 × magnification)	220
Figure 3.76	Effects of recombinant proteins on the invasiveness of MCF-7	222
Figure 3.77	Effects of recombinant proteins on the invasiveness of MDA-MB-231	223

## LIST OF SYMBOLS, ABBREVIATIONS AND ACRONYMNS

°C	Degree Celsius
%	Percent
®	Registered Trademark
<	Less Than
>	More Than
1×	1 Time
µg	Microgram (s)
µL	Microlitre (s)
A <sub>260</sub>	Absorbance at 260 nm Wavelength
A <sub>280</sub>	Absorbance at 280 nm Wavelength
ATCC	American Type Culture Collection
BLAST	Basic Local Alignment Search Tool
bp	Base Pair (s)
BSA	Bovine Serum Albumin
DNA	Deoxyribonucleic Acid
dNTPs	Deoxyribonucleoside Triphosphates
<i>E. coli</i>	<i>Escherichia coli</i>
ELISA	Enzyme-Linked Immunosorbent Assay
g	Gram (s)
H <sub>2</sub> O	Water
HCl	Hydrogen Chloride
HRP	Horseradish Peroxidase

kb	Kilobase (s)
kDa	Kilodalton (s)
LB	Luria Broth
M	Molar (s)
mg	Milligram (s)
mg/mL	Milligram (s) per Millilitre (s)
min	Minute (s)
mL	Millilitre (s)
mM	Millimolar (s)
NCBI	National Center for Biotechnology Information
ng/μL	Nanogram (s) per Microlitre (s)
nm	Nanometer (s)
OD	Optical Density
PBS	Phosphate Buffered Saline
PCR	Polymerase Chain Reaction
pH	Power of Hydrogen
rpm	Revolutions per Minute
SDS	Sodium Dodecyl Sulfate
SDS-PAGE	Sodium dodecyl Sulfate-polyacrylamide Gel Electrophoresis
UV	Ultraviolet
v/v	Volume Per Volume
w/v	Weight Per Volume

**PENGHASILAN DAN PENULENAN PROTEIN REKOMBINAN PENARIK  
RESEPTOR KEMOKINA D6 DAN DARC SERTA KESANNYA KE ATAS  
MIGRASI DAN INVASI SEL MDA-MB-231 DAN MCF-7**

**ABSTRAK**

D6 dan DARC telah dilaporkan sebagai penarik reseptor kemokina dalam kajian kanser. Penglibatan D6 dan DARC dalam kanser payudara telah dikaji dan dilaporkan berkorelasi negatif dengan perkembangan dan metastasis sel kanser payudara. Kajian ini bertujuan membina klon rekombinan D6 dan DARC, mengekspres, menganalisis dan menuliskan protein rekombinan dan kemudian menentukan kesan protein rekombinan ke atas migrasi dan invasi sel kanser payudara. Gen D6 dan DARC dalam sel MDA-MB-231 diampifikasikan oleh RT-PCR satu-langkah dengan primer gen spesifik dan polimerase Pfu DNA pada mulanya. Selain itu, DARC juga diampifikasikan dengan PCR menggunakan polimerase DNA Phusion. Bagi setiap klon, dua pasang primer spesifik digunakan untuk menghasilkan jujukan nukleotida penuh yang kemudian diklonkan ke dalam vektor ekspresi pPICZ dan pPICZ $\alpha$ . Pembinaan klon TA dan analisis penjujukan DNA menunjukkan pepadanan sempurna antara TA-D6 dan TA-D6 $\alpha$  dengan jujukan DNA rujukan. Walau bagaimanapun, penggantian bes diperhatikan pada lokasi 131 bp TA-DARC dan TA-DARC $\alpha$ . Mutagenesis tapak terarah telah dijalankan untuk membetulkan ketidakpadanan itu. Penjanaan vektor ekspresi yis rekombinan dilakukan dan penjujukan DNA dijalankan semula untuk mengesahkan ligasi sebingkai gen yang diingini dengan jujukan hujung N dan C vektor-vektor

ekspresi. Analisis ClustalW sekali lagi menunjukkan ketidakpadanan pada 131 bp pPICZ-DARC dan pPICZ-DARC $\alpha$ , selaras dengan penemuan TA-DARC dan TA-DARC $\alpha$ . Ini mencadangkan bahawa penggantian bes yang ditemui bukan satu ketidakpadanan tetapi mungkin merupakan polimorfisme di mana jujukan nukleotida DARC daripada sel MDA-MB-231 mempunyai satu nukleotida yang berlainan pada 131 bp dan jujukan gen tersebut telah disimpan dalam GeneBank (ID: JX081310). Selepas itu, elektrotransformasi *Pichia* GS115 telah dijalankan untuk membolehkan integrasi vektor ekspresi yis rekombinan linear ke dalam genom yis. Selepas penyaringan antibiotik dan analisis PCR untuk mengesahkan integrasi gen yang diinginkan dalam genom yis, klon-klon positif dikulturkan atas medium dengan peningkatan kepekatan Zeocin<sup>TM</sup>. Klon-klon yang dapat merintang kepekatan Zeocin<sup>TM</sup> sehingga 2 mg/ml dipilih untuk ekspresi protein rekombinasi. Profil awal ekspresi protein rekombinan menunjukkan penghasilan protein heterologus yang rendah oleh klon pPICZ $\alpha$ . Oleh itu, hanya klon pPICZ yang menghasilkan protein rekombinan intraselular dipilih untuk kajian ekspresi selanjutnya. Pengoptimuman parameter fizikal dan kimia terpilih telah dilakukan dan ekspresi protein rekombinan intraselular terlarut didapati meningkat secara mendadak dengan peningkatan sebanyak 1011.97% untuk klon rekombinan D6, 451.75% untuk klon rekombinan DARC dan 394.72% untuk klon rekombinan DARC bermutasi. Parameter yang dioptimumkan ialah: BMMY pada pH 6.0, saiz inokulum pada OD<sub>600</sub> 2.5 (untuk D6) dan 1.0 (untuk DARC dan DARC bermutasi), induksi dengan 1.0% (v/v) metanol sekali setiap 24 jam dan inkubasi pada 16°C selama 48 jam. Protein rekombinan kemudian ditulenkan dengan menggunakan kromatografi afiniti dengan resin Cobalt. Analisis SDS PAGE dan Western Blot yang telah dioptimumkan menunjukkan bahawa rekombinan D6, DARC dan DARC bermutasi hasilan yis yang

telah dituliskan mempunyai berat molekul yang lebih tinggi berbanding dengan berat molekul kiraan teori. Selepas itu, protein rekombinan yang telah dituliskan digunakan dalam kajian berasaskan sel untuk menguji aktiviti biologinya. Ujian viabiliti sel menunjukkan bahawa rekombinan D6, DARC dan DARC bermutasi tidak mempengaruhi viabiliti sel dengan ketara dan dengan itu mencadangkan bahawa mereka tidak terlibat dalam kematian sel kanser payudara. Ujian penyembuhan luka menunjukkan bahawa kehadiran rekombinan D6, DARC atau DARC bermutasi pada 10 µg/ml menghalang migrasi sel kanser payudara dengan optimumnya. Kajian ELISA menunjukkan hubungan songsang antara protein-protein rekombinan dengan tahap CCL2 dalam sel yang dirawat. Ujian migrasi menggunakan “Boyden chamber” memaparkan fungsi protein rekombinan dalam merencat aktiviti kemotaksis sel-sel yang dirawat. Ujian invasi menggunakan “Boyden chamber” yang dilapisi matrigel menunjukkan keupayaan protein rekombinan dalam menyekat invasi sel yang dirawat. Dalam perbandingan kesan tunggal dan kesan kombinasi protein rekombinan, gabungan D6 dan DARC pada nisbah 1:1 (10 µg/ml) didapati paling baik dalam mengurangkan tahap CCL2 dalam sel-sel yang dirawat dan seterusnya menghalang migrasi dan invasi sel-sel yang dirawat. Ini telah menunjukkan bahawa rekombinan D6, DARC dan DARC bermutasi hasilan yis yang dituliskan bukan sahaja bertindak sebagai pengawal selia negatif bagi migrasi dan invasi sel kanser payudara malah kesan perencatannya adalah lebih tinggi apabila digunakan bersama.

**THE PRODUCTION AND PURIFICATION OF D6 AND DARC CHEMOKINE  
DECOY RECEPTOR RECOMBINANT PROTEINS AND THEIR EFFECTS ON  
MIGRATION AND INVASION IN MDA-MB-231 AND MCF-7 CELLS**

**ABSTRACT**

D6 and DARC had been reported as a decoy chemokine receptor in cancer study. The involvement of D6 and DARC in breast cancer had been investigated and it was reported to negatively correlate with the progression and metastasis of breast cancer cells. This study aimed to construct recombinant clones of D6 and DARC, express, analyze and purify the proteins and then determine the effects of the recombinant proteins on breast cancer cell migration and invasion. D6 and DARC genes in MDA-MB-231 cell line were first amplified by one-step RT-PCR with gene specific primers and Pfu DNA polymerase. Besides, DARC was also amplified by PCR using Phusion DNA polymerase. For each of the clones, two pairs of specific primers were used to generate full length nucleotide sequences which were cloned into pPICZ and pPICZ $\alpha$  expression vectors. The construction of TA clones and DNA sequencing analysis showed perfect match of TA-D6 and TA-D6 $\alpha$  to reference sequence. However a base substitution was observed at 131 bp of TA-DARC and TA-DARC $\alpha$ . Site-directed mutagenesis was carried out to correct the mismatch. Generation of recombinant yeast expression vector was performed and DNA sequencing was carried out again to confirm in frame ligation of gene of interest to the N and C-terminal sequences of expression vectors. ClustalW analysis again showed a mismatch at 131 bp of pPICZ-DARC and

pPICZ-DARC $\alpha$ , which was identical to the findings of TA-DARC and TA-DARC $\alpha$ . This suggested that the base substitution found was not a mismatch but might be a polymorphism where the nucleotide sequence of DARC from MDA-MB-231 cells possess a different nucleotide at 131 bp and the gene sequence had been deposited to GeneBank (ID: JX081310). After that, electrotransformation of *Pichia* GS115 was carried out to allow integration of linearized recombinant yeast expression vectors into yeast genome. Upon antibiotic screening and PCR analysis to confirm the integration of gene of interest in the yeast genome, the positive clones were plated at increasing Zeocin<sup>TM</sup> concentrations. Clones which were able to confer resistance to Zeocin<sup>TM</sup> concentration of up to 2 mg/ml were selected for recombinant protein expression. Initial profile of recombinant protein expression showed low yields of heterologous proteins from pPICZ $\alpha$  clones. Hence, only pPICZ clones, which expressed recombinant protein intracellularly were selected for further expression studies. Optimizations of selected physical and chemical parameters were performed and the intracellular expression of soluble recombinant proteins were found to increase dramatically with an increase of 1011.97% for recombinant D6, 451.75% for recombinant DARC and 394.72% for recombinant mutated DARC. The optimized parameters are: BMMY at pH 6.0, inoculum size at OD<sub>600</sub> of 2.5 (for D6) and 1.0 (for DARC and mutated DARC), induction with 1.0% (v/v) of methanol once every 24 hours and incubated at 16°C for 48 hours. The recombinant proteins were then purified by using affinity chromatography with Cobalt resins. SDS PAGE analysis and optimized Western Blot showed that the purified yeast expressed recombinant D6, DARC and mutated DARC were higher in apparent molecular weight compared to the theoretical calculated molecular weight. The purified recombinant proteins were then used in cell based studies to test on its

biological activity. Cell viability tests showed that recombinant D6, DARC and mutated DARC did not affect the viability of cells significantly and thus suggested that they were not involved in breast cancer cell death. Wound healing assays showed that the presence of recombinant D6, DARC or mutated DARC at 10 µg/ml inhibited the migration of breast cancer cells optimally. ELISA showed the inverse relationship between the recombinant proteins and CCL2 level in treated cells. Migration assay using Boyden chamber demonstrated the function of the recombinant proteins in inhibiting chemotaxis activity of treated cells. Invasion assay using matrigel coated Boyden chamber further showed the ability of the recombinant proteins in inhibiting the invasion property of treated cells. Comparing single and combinatorial effects of the recombinant proteins, the combination of D6 and DARC at ratio 1:1 (10 µg/ml) was found to be the best in reducing CCL2 level in treated cells and subsequently inhibit the migration and invasion of treated cells. It was shown that the purified yeast expressed recombinant D6, DARC and mutated DARC are not only negative regulators of breast cancer cell migration and invasion but the inhibition effects were greater when they were used in combination.

## CHAPTER ONE


### INTRODUCTION

#### 1.1 Breast cancer

Breast cancer is the most common cancer in women in most parts of the world. Majority of the breast cancer patients were found to surrender to this disease due to cancer invasion and metastasis (Chew *et al.*, 2013). In oncology study, breast cancer research had become one of the most evolving fields (Vora *et al.*, 2009). To date, with the advanced understanding of key molecular features, breast cancer is no longer considered a single disease but a combination of different subtypes with different biological behaviours and clinical outcomes (Sandhu *et al.*, 2010). Novel molecules and new diagnostic methods are being discovered and developed constantly, globally. Recently, the identification of various signaling pathways implicated in the cellular processes of breast cancer cells has drawn the attention of researchers worldwide. The involvement of growth factors or signaling molecules in breast cancer cell proliferation and invasion were reported worldwide (Adams *et al.*, 1991; Adnane *et al.*, 1991; Cabioglu *et al.*, 2009; Ahmad *et al.*, 2011). For examples, chemokines and chemokine receptors were reported to be involved in cancer growth and metastasis (Addison *et al.*, 2004; Balkwill, 2004; Ali and Lazennec, 2007; Allavena *et al.*, 2011; Tang *et al.*, 2011; Zeng *et al.*, 2011). Noteworthy attention had been placed on mediators which are known to be inflammatory, such as cytokines and chemokines (Balkwill and Mantovani, 2001; Coussens and Werb, 2002; Allavena *et al.*, 2008).

### **1.1.1 Breast cancer in Malaysia**

Ho *et al.* (2017) reported that breast cancer is the fourth leading cause of death in Malaysia. According to the Malaysia Breast Health Information Centre, there is a marked geographical variation in the breast cancer incidence rate where the statistics are more frightening in Western countries, such as the U.S., than in developing countries. In the U.S., approximately 184,000 new breast cancer cases are detected annually. The breast cancer incidence is also rising in Malaysia. Malaysian National Cancer Registry Report 2007-2011 (Azizah *et al.*, 2016) showed that breast cancer is the most common cancer among females in Malaysia during the period of 2007-2011. Colorectal, cervix uteri, ovary and lung cancer are the other 4 common cancers after breast cancer. According to the report, breast cancer constituted 32.1% of all the cancers in Malaysian females. 56.9% of the breast cancer cases were detected at stage I and stage II. Breast cancer incidence was found to be the highest in Chinese females followed by Indian and Malay. Moreover, the report also showed that the highest cumulative risk was observed in Chinese females and the lowest in Malay females. Furthermore, lifetime risk was found to be 1 in 30 as a big total. Lifetime risk in Chinese was 1 in 22, 1 in 24 for Indian and Malay was observed to be 1 in 35. The age-standardization rate (ASR) distribution according to state among female breast cancers in Malaysia from year 2007-2011 is presented in Figure 1.1.



Adopted from Azizah *et al.* (2016)

**Figure 1.1** The age-standardization rate (ASR) distribution according to state in Malaysia, 2007-2011

### **1.1.2 Breast cancer studies in Malaysia**


According to the Cancer Research Initiatives Foundation (CARIF), current breast cancer research in Malaysia includes:

- Determination of genes that cause breast cancer and contribute to an increased risk of breast cancer.
- Identification of biomarkers that may be used in identification and early detection of breast cancer and development of these biomarkers into clinically useful tools.
- Identification and development of methods for the rapid and robust identification of individuals who are at risk of breast cancer.
- Development of appropriate screening, preventive and therapeutic strategies for individuals who are at high risk for breast cancer.
- Discovering ways to prevent and treat breast cancer such as using drugs, plant extracts, herbal tualang honey and other traditional medicines.

However, investigation of the invasiveness of breast cancer cells by targeting the invasion-associated molecules, such as CCL2 remains rare.

## 1.2 Chemokines and chemokine receptors in cancer

Chemokines are small proteins range from approximately 8 to 17 kDa and belong to a family of chemoattractant cytokines, which can be induced by cytokines, growth factors and pathogenic stimuli. Chemokines mostly involved in chemoattraction to regulate the migration of cells, particularly leukocyte, to inflammation sites (Luster, 1998). Charo and Ransohoff (2006) reported that chemokines were also involved in other cytokine-like activities, such as proliferation, apoptosis susceptibility, angiogenesis and fibrosis. Chemokine structure comprises an N-terminal loop region, three-strand antiparallel  $\beta$ -sheets forming the typical core fold of the chemokines and a C-terminal  $\alpha$  helix which overlays the  $\beta$ -sheet. The production of chemokines can be either constitutive or induced by environmental stimuli. Thus, chemokines can be subdivided into two major categories, namely homeostatic and inflammatory chemokines. Constitutive chemokines always regulate homeostatic trafficking of leukocytes and lymphocyte recirculation under normal or steady state condition; whereas inflammatory chemokines are generated in response to inflammatory and immune stimuli which subsequently direct leukocytes to inflamed peripheral tissues (Chew *et al.*, 2013). Chemokines are classified into four subfamilies, C, CC, CXC and CX3C (where X is any amino acid), based on the number and spacing of the first two cysteines in the amino terminus (Slettenaar and Wilson, 2006). The schematic representation of these four different groups of chemokines is shown in Figure 1.2.




Adopted from Ali and Lazenec (2007)

**Figure 1.2** Chemokines are classified into four major groups, namely CXC, CC, CX3C and XC (where X is any amino acid)

Besides leukocyte chemoattraction, Ali and Lazennec (2007) reviewed that chemokines were the first members of the cytokine family to show interaction with G-protein-coupled receptors (GPCR). These chemokine receptors are known to be embedded in the lipid bilayer of the cell surface and also to possess seven transmembrane domains. These members of G-protein-coupled receptor (GPCR) superfamily have single polypeptide chains that consist of three extracellular loops and also three intracellular loops. There is also a serine/threonine-rich intracellular carboxyl-terminal domain and an acidic amino-terminal extracellular domain which is involved in the binding of ligand. Besides, there are important conserved motifs in chemokine receptors, such as Thr-X-Pro; where X refers to any amino acid, Asp-Arg-Tyr (DRY) and Glu-Leu-Arg (ELR) (Figure 1.3). These conserved motifs play a role in signaling.

Figure 1.3 depicted the interaction of chemokine receptors with endothelial cells. Chemokines interact with endothelial cells via glycosaminoglycans (GAGs). Some chemokines bind GAGs through C-terminal  $\alpha$ -helix amino acids, whereas other chemokines bind GAGs via residues in the loop that links N terminus with the first  $\beta$ -strand and residues in the loop which links to second and third  $\beta$ -strands (Mantovani *et al.*, 2006).




Adopted from Mantovani *et al.* (2006)

**Figure 1.3** The interaction of chemokine receptors with endothelial cells

- (a) Some chemokines bind GAGs through C-terminal  $\alpha$ -helix amino acids
- (b) Some chemokines bind GAGs via residues in the loop that links N terminus with the first  $\beta$ -strand and residues in the loop which links to second and third  $\beta$ -strands.

Chemokines bind to the seven transmembrane spanning G-protein-coupled receptors (GPCRs) to exert their actions. Typical receptor then specifically binds to its ligand leading to typical signaling pathways. Upon binding of chemokine receptor to its ligand, the  $\beta\gamma$  subunits of heterotrimeric G-protein were released. The detached  $\beta\gamma$  subunits activate phosphoinositide-specific phospholipase C (PLC) isoenzymes directly. This leads to the formation of inositol-1, 4, 5-triphosphate. The rise of intracellular calcium concentration subsequently leads to chemotaxis (Ali and Lazennec, 2007; Yadav *et al.*, 2010). However, PI3K pathway is another alternative. Activation of MAP Kinase pathway following PI3K will ultimately leads to chemotaxis too (Roussos *et al.*, 2011) (Figure 1.4). The short and transient signals mediated by the chemokine receptor to induce chemotaxis can be terminated rapidly by phosphorylation at multiple sites of the cytoplasmic C-terminus, homologous and heterologous desensitization and internalization eventually (Yadav *et al.*, 2010).



Adopted from Ali and Lazenec (2007)

**Figure 1.4** The binding of chemokine receptor to respective ligand elicits a cascade of signaling pathways

Allavena *et al.* (2011) reported that serving as key-player in cancer-related inflammations, chemokines was found affecting a variety of tumor progression pathways. Those pathways include cancer cell survival and proliferation, cell migration and cell invasion. Chemokine ligands and its receptors are plentifully expressed in cancer cells of chronic inflammatory conditions.

In the recent years, chemokines and chemokine receptors have been widely reported on their roles in the process of malignant progression (Muller *et al.*, 2001; Ben-Baruch, 2006; Rollins, 2006; Ali and Lazennec, 2007; Ben-Baruch, 2008). Cancer cells were observed to produce chemokines and chemokine receptors which were able to respond specifically to these chemokines, thus forming a complex chemokine network which is involved in influencing tumor cell survival, spreading and growth (Balkwill, 2004). Typical receptor binds specifically to its ligand and leading to typical signaling pathway. However, a few “silent” receptors are included in chemokine system as they bind to respective ligands with high affinity but do not bring out signal transduction. The details on these silent receptors are discussed in Section 1.4.

Raman *et al.* (2011) stated that chemokines play a vital role in physiology, homeostasis and also pathogenesis of tumors and their metastasis. The applications of chemokines and chemokine receptors in pre-clinical and clinical settings suggested chemokine system as an important target for the improvement of current therapeutic strategies (Allavena, 2011).


### 1.2.1 CCL2 and breast cancer

Chemokine (C-C motif) ligand 2 (CCL2), also referred to as monocyte chemoattractant protein-1 (MCP-1), is a member of the C-C chemokine family and is primarily secreted by monocytes, macrophages and dendritic cells (Conti and Rollins, 2004). It is known as a potent chemoattractant for monocytes, memory T-lymphocytes and also natural killer cells (NK cells). It is one of the soluble growth factors, detected in high level in serum and not presented on cell surface (Jiang *et al.*, 1990; Jiang *et al.*, 1991; Proost *et al.*, 2006). An elevated serum level of CCL2 has been found to be significantly associated with breast cancer invasion and metastasis and higher tumorigenicity phenotype of breast cancer cells (Neumark *et al.*, 1999; Wang *et al.*, 2006). CCL2 expression in breast carcinomas was reported to correlate with the lack of estrogen receptor (ER) and expression of progesterone receptor (Chavey *et al.*, 2007).

The tumor associated macrophages (TAM) are myeloid monocytic cells which are employed to the tumor cells via CCL2. TAM was correlated to invasive phenotype and poor diagnosis (Mantovani *et al.*, 2006b; Sozzani *et al.*, 2007; Lewis and Pollard, 2006). Besides serving the role as pro-maglinancy in breast cancer, CCL2 expressed by TAM and/or tumor cells was observed to significantly correlate with microvessel density and vessel invasion of tumor cells (Saji *et al.*, 2001; Balkwill, 2004; Wang *et al.*, 2006; Wu *et al.*, 2008; Galzi *et al.*, 2010; Mantovani *et al.*, 2010; Ueno *et al.*, 2000). TAM-expressed CCL2 was also found to be significantly related to the expression of membrane type 1-matrix metalloproteinase (MT1-MMP), tumor necrosis factor  $\alpha$  (TNF $\alpha$ ), thymidine phosphorylase (TP) and other angiogenic factors.

Figure 1.5 showed the suggested mechanisms interceding roles of CCL2 and breast cancer. Different from normal breast cells, breast cancer cells express CCL2 in high level. Besides, CCL2 was also released by different cells types at the tumor microenvironment. Figure 1.5A showed that CCL2 promotes angiogenesis and stimulates the tumor cells to release MMP, subsequently induces the motility of tumor cells. This explains the roles of CCL2 in breast cancer cell migration and invasion. Activities of CCL2 further aggravate the effects of TAM-derived pro-maglinancy factors at the tumor sites (Figure 1.5B). This lead to the growth and establishment of tumor cells at primary tumor sites. Tumor cell migration and dissemination also take place. Ultimately, the tumor-promoting activities of CCL2 lead to metastatic spread of tumor cells to preferred metastatic sites such as lungs, bones and liver (Figure 1.5C)

In summary, CCL2 plays a causative role in the maglinancy of breast cancer (Soria and Ben-Baruch, 2008). Nam *et al.* (2006) used MDA-MB-231, the metastatic human breast cancer cells to study the direct effect of CCL2 in breast cancer maglinancy. CCL2 knocked down by shRNA in the study was observed to result in approximately 3-fold decrease of metastatic lung nodules in mice. Salcedo *et al.* (2000) reported significant inhibition of lung metastasis and increment of mice survival rate with CCL2 blocking by neutralizing antibodies in MDA-MB-231 cells.



Adopted from Soria and Ben-Baruch (2008)

**Figure 1.5** Roles of CCL2 on the malignancy of breast cancer

### **1.3 Role of chemokines and chemokine receptors in cancer cell migration and invasion**

Expression of chemokine receptors has been found to be restricted and specific in many cancer cells. Beside aiding in cell growth and survival, chemokine receptors were also found to be facilitating the characteristic patterns of metastasis (Slettenaar and Wilson, 2006).

To date, CXCR4 is the most overexpressed and best characterized chemokine receptor in cancer cells that demonstrated the involvement of CXCR4 in cancer cells metastasis. CXCR4 was found up regulated in more than 20 different types of tumor histotypes (Mantovani *et al.*, 2010). In hematopoietic stem cells, CXCR4 was used to reach and settle down in bone marrow niches. The expression of CXCR4 in primary tumor has shown positive co-relationship with the degree of lymph node metastasis, poor patient overall survival and also tumor grade (Ali and Lazenec, 2007). Besides, the expression of CXCR4 had also been linked to the metastasis ability of breast cancer cells to the lung (Helbig *et al.*, 2003).

Other CXC chemokine receptors had also been reported in the malignancy of different types of hematological neoplasia either alone or in combination. For examples, CXCR and CXCR2 in malignant melanoma (Varney *et al.*, 2006), CCR5, CCR9 and CX3CR1 in prostate cancer (Murphy *et al.*, 2005). Besides, CXCR3 was found to be associated with the development of lymph node metastasis in murine melanoma


(Kawada *et al.*, 2004) and colon cancer (Kawada *et al.*, 2007) and lung metastasis in murine mammary cancer models (Walser *et al.*, 2006; Ma *et al.*, 2009). Apart from that, CXCR5 had been observed to promote liver metastasis of colorectal carcinoma (Meijer *et al.*, 2006) whereas CXCR6 was found to be associated with inhibition of tumor growth in breast and renal cancer (Meijer *et al.*, 2008; Gutwein *et al.*, 2009) but up regulated in advanced stage of prostate cancer (Darash-Yahana *et al.*, 2009).

CCR7 had been used as a potential marker in prediction of breast and colorectal cancer (Gunther *et al.*, 2005). Lower survival rates were observed from patients with CCR7 positive carcinomas than those with CCR7 negative cancer cells. Besides, CCR7 was also found to be associated with lymph node metastasization, lymphatic invasion and also stage of tumor (Takanami, 2003). Other CC chemokine receptor such as CCR6 was observed to play significant roles in organ selective liver metastasis of colorectal cancer (Ghadjar *et al.*, 2006). CCR9 was reported to be related to intestinal melanoma metastasis (Letsch *et al.*, 2004) while CCR5-positive cancer cells were observed to enhance the growth and metastatic ability of tumor cells upon interacting with CCL5 (Karnoub *et al.*, 2007). Besides, the expression of CX3CR1 by prostate cancer cells was observed to mediate metastasis to bone (Shulby *et al.*, 2004). It was also reported to be expressed by pancreatic adenocarcinoma and was implicated in perineural invasion and tumor recurrence (Marchesi *et al.*, 2008).

#### **1.4 Decoy chemokine receptor proteins**

Many studies have recently reported findings on the atypical action of chemokine receptor proteins (Figure 1.6). These receptor proteins were termed “decoy proteins” or “scavenger proteins” due to the fact that the binding of these proteins to the respective ligands does not lead to typical signaling pathway, but intercept the respective pathway and neutralize the action of chemokines (Wang *et al.*, 1998; Mantovani *et al.*, 2006; Wang *et al.*, 2006; Wu *et al.*, 2008; Galzi *et al.*, 2010). Hence they are also well known to be “intercepting receptors” as the decoy chemokine receptors confiscate chemokines with no activation of respective signaling pathway (Galzi *et al.*, 2010; Hansell *et al.*, 2006). The binding of chemokines without triggering G protein signaling pathway is a way of regulating chemokine activity and may function as a tumor suppressor (Mantovani *et al.*, 2006; Graham, 2009). It has emerged as a general strategy in recent years to tune the actions of cytokines and growth factors.

The decoy chemokine receptors that had been reported are Duffy antigen for chemokines (DARC), D6 (which is also known as CCBP2) and also CCX-CKR (or CCRL1). Different from antibodies and small molecule receptor antagonists, chemokine decoy receptors generally have broad specificity of ligands that are recognized by different receptors (Mantovani *et al.*, 2006a). In this study, DARC and D6 will be expressed and hence details of DARC and D6 are described as follows.



Adopted from Galzi *et al.* (2010)

**Figure 1.6** A global illustration of the routes taken by chemokines with different types of receptors

Route 1: Chemokine binding with a typical specific receptor leads to signalling in the cell that expresses the receptor.

Route 2: Chemokine binding with an interceptor intracellularly leads to either chemokine degradation or transcytosis.

Route 3: Chemokine binding with a soluble interceptor leads to ligand sequestering.


Route 4: Soluble interceptor binding prevents chemokine binding to glycoaminoglycans, which results in a collapse of the chemotactic gradient.

### 1.4.1 D6

D6 was first cloned from haematopoietic stem cells (Nibbs *et al.*, 1997) and placenta (Bonini *et al.*, 1997) in the 1990s. It is also known as CCBP2 (Locati *et al.*, 2005) or ACKR (atypical chemokine receptor) 2 (Wilson *et al.*, 2017). It was highly expressed by endothelial cells of skin, gut and lung and also lymphatic endothelium, trophoblast, leukocyte, malignant vascular tumour, T-cell large granular lymphocyte leukemia cells, choriocarcinoma (Nibbs *et al.*, 2001; Martinez de la Torre *et al.*, 2007; Zeng *et al.*, 2011) and human breast cancer cells (Wu *et al.*, 2008).

D6 was observed to bind almost all pro-inflammatory CC chemokines. However, it does not recognize and bind to homeostatic CC-chemokines or other families such as CXC-chemokines (Mantovani *et al.*, 2006). The binding of D6 to its ligand happened in such a way that D6 takes part in ligand-independent constitutive internalization. D6 enters cell through endosomal compartments rapidly upon binding with chemokine. Then, it detaches from the ligand and this made the internalized chemokines remain trapped in the cell. The trapped chemokines are then targeted for degradation by cellular organelle (Xu *et al.*, 2007). At the same time, D6 recycles back to cell surface to bind new chemokine and rapidly enter the cell through endosomal compartments again (Chew *et al.*, 2013). The repeated rounds of chemokine internalization leads to reduction of free extracellular pro-inflammatory chemokines and subsequently down regulate respective chemokine related biological activities (Figure 1.7). The binding mechanism of D6 to its ligands had been reported widely. Researches found that D6 took part in

chemokine degradation and at the same time reduced the inflammatory activity of CC chemokines (Savino *et al.*, 2009). This agrees with the findings from Fra *et al.* (2003), Bonecchi *et al.* (2004) and Weber *et al.* (2004) that D6 can speedily internalize and degrade its ligands. Mantovani *et al.* (2006) also reported similar findings that D6 mediates chemokine degradation but does not mediate chemokine transfer through cell monolayer.




**Figure 1.7** The coordinated actions of DARC and D6 in peripheral tissues

Adapted from Bonecchi *et al.* (2008)

- Expression of DARC takes place on blood vessels and erythrocytes. Besides acting as chemokines' depot on erythrocytes, it serves as decoy chemokine receptors on endothelial cells and transport chemokines through cell barriers by transcytosis.
- D6 is expressed at lymphatic endothelium and leukocytes at lower levels. It acts as scavenger to degrade pro-inflammatory chemokines, preventing them from transferring to lymph nodes.

D6 was a decoy chemokine receptor as it was found lacking of sequence motif used for G-protein coupling and also signaling functions of respective chemokine receptors (Mantovani *et al.*, 2001). D6 is structurally typical of chemokine receptor family and thus it has the similar gene structure with signaling CC chemokine receptors (Nibbs *et al.*, 2003). However, alterations were observed in D6 conserved motif. Instead of DRYLAIV motif on the second intracellular loop of GPCRs, it was observed being altered to DKYLEIV in D6 (Nibbs *et al.*, 2003). DRYLAIV motif is essential for ligand-induced signaling, having the conserved motif altered, making D6 a silent chemokine receptor. Figure 1.8 showed the presence of D6 in chemokine system to compete with signaling chemokine receptors to bind with its ligand. The binding of D6 to its ligand will not elicit signal transduction so does the cascade of signaling pathways. Wu *et al.* (2008) reported that over expression of D6 reduced chemokines such as CCL2 and CCL5, subsequently inhibited proliferation of breast cancer cells *in vitro* and *in vivo*. The tumorigenesis of lung metastasis *in vivo* was observed to be inhibited too. Coexpression of D6 in invasive breast cancer cells was observed to be negatively correlated with lymph node status and tumor stage (Zeng *et al.*, 2011).



Adopted from Mantovani *et al.* (2006)

**Figure 1.8** D6, the decoy chemokine receptor proteins compete with signaling chemokine receptor for ligands

### 1.4.2 DARC

DARC or Duffy Antigen was originally reported by Horuk *et al.* (1993) as the receptor on erythrocyte to bind chemokines in infection by malaria parasites, the *Plasmodium vivax* and *P. knowlesi*. It was then well known and intensively studied in malaria research as its role is remarkable in this aspect. Pogo and Chaudhuri (2000) reported that human red blood cells which are Duffy-negative are resistant to malaria parasite infection. Similar results were reported by Miller *et al.* (1975) that the infection of malaria parasite in Duffy-positive individuals happened occasionally but Duffy-negative individuals were not prone to the infection. All the four extracellular domains in DARC were shown to be involved in the interaction between DARC and chemokines but the first extracellular domain was found vital for the interactions of erythrocyte-binding proteins from malarial parasites (Choe *et al.*, 2005; Tournamille *et al.*, 2003; Chitnis *et al.*, 1996).

DARC was found to be expressed by vascular endothelium, red blood cells and also several tumors (Wang *et al.*, 2006; Galzi *et al.*, 2010). The expression of DARC on endothelial cells suggested its role in vascular biology (Peiper *et al.*, 1995). Rot (2005) showed that DARC interacts with many inflammatory chemokines on red blood cells and may act as a reservoir besides involving in transendothelial chemokine transport process (Figure 1.7). It was found to interact with 11 pro-inflammatory CXC and CC chemokines but not the homeostatic one (Gardner *et al.*, 2004; Mantovani *et al.*, 2001; Wang *et al.*, 2006; Wu *et al.*, 2008; Galzi *et al.*, 2010). Being promiscuous chemokine